Abstract

Combating the consequences of COVID-19, a disease caused by the new coronavirus infection SARS-CoV-2, is a serious and very urgent task facing modern medicine. COVID-19 often has a severe course and is accompanied by multiple organ damage, systemic immune inflammation, coagulopathy, neuroendocrine and metabolic disorders. Even with a relatively favorable course, the consequences of SARS-CoV-2 infection can be degenerative changes in many organs (pulmonary fibrosis, cardiosclerosis), various functional and psychoemotional disorders. As a result, in 10–50% of patients, various unpleasant symptoms persist for a long time after the acute manifestations of COVID-19 subside and the virus is eliminated. This pathology is referred to as “post-COVID syndrome” (PCS). The main elements of PCS are chronic pain, fatigue, and psychoemotional problems. Functional disorders, autoimmune processes, and severe psychological distress after COVID-19 can cause the development and exacerbation of diseases characterized by chronic pain and fatigue, such as fibromyalgia and chronic fatigue syndrome. Therapy and prevention of PCS include correction of functional disorders, pain control, and consistent physical, psychological, and social rehabilitation.

Highlights

  • Combating the consequences of COVID-19, a disease caused by the new coronavirus infection SARS-CoV-2, is a serious and very urgent task facing modern medicine

  • In 10–50% of patients, various unpleasant symptoms persist for a long time after the acute manifestations of COVID-19 subside and the virus is eliminated

  • Functional disorders, autoimmune processes, and severe psychological distress after COVID-19 can cause the development and exacerbation of diseases characterized by chronic pain and fatigue, such as fibromyalgia and chronic fatigue syndrome

Read more

Summary

Тканевая гипоксия

В исследовании германских ученых частота скелетно-мышечной боли у лиц, перенесших COVID-19, составила 12% [36]. После выписки из стационара частота хронической боли (продолжавшейся более 3 месяцев) у пациентов после COVID-19 составила 19,6%, в контрольной группе – 1,4% (р=0,002). [38], оценивших состояние 1733 госпитальных пациентов (средний возраст – 57 лет; 52% мужчин), перенесших COVID-19, при достаточно длительном сроке наблюдения – в среднем через 186 дней (95% ДИ: 175–199 дней). Через 6 месяцев после выписки утомляемость и мышечная слабость отмечались у 66%, 59% и 81%, нарушение сна – у 27%, 26% и 26%, боль в суставах – у 12%, 8% и 15%, миалгии – у 3%, 2% и 3%, боль в груди – у 4%, 4% и 9% больных соответственно. В настоящее время нет четких данных об увеличении частоты этих заболеваний у лиц, которые перенесли инфекцию SARS-CoV-2.

Миалгии Боль в груди
Findings
Принципиальные подходы для профилактики и терапии ПКС
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call